Recalls, market withdrawals and safety alerts, and how FDA tells them apart

Between Jan. 1 and Oct. 21, 2026, FDA posted 40 drug recall announcements on its drug recalls page⁸, according to a GxRadar count of the page's spreadsheet export. Over nearly the same stretch, through Oct. 28, the agency's recall database logged 297 separate drug recall events covering 704 product records, according to GxRadar's analysis of openFDA enforcement data¹⁵.

The gap is not a backlog. FDA runs two public channels for removals, and a third set of actions stays out of the main one entirely. Which channel a removal lands in depends on a handful of definitions written into federal regulations in the 1970s.

Those definitions sit in 21 CFR 7.3¹. They separate a recall from a market withdrawal, a stock recovery and a correction, and the label decides whether FDA assigns a hazard class and whether the action is listed in the weekly Enforcement Report. This piece walks through the four terms, shows how the Enforcement Report records the ones that count, and explains where FDA's safety alerts and drug safety communications fit, since they are often confused with recalls.

Four terms in 21 CFR 7.3

Legal exposure is the test. A recall, under section 7.3(g), is a firm's removal or correction of a marketed product that FDA considers to be in violation of the laws it administers "and against which the agency would initiate legal action, e.g., seizure." The same paragraph says a recall "does not include a market withdrawal or a stock recovery."

A correction is a method, so it can sit inside a recall. Relabeling cartons that show the wrong strength, for example, is a correction, and if FDA considers the original label violative the action is also a recall that gets a class.

FDA's own background page on recalls⁴ gives the standard example of a market withdrawal: a product removed because of tampering, "without evidence of manufacturing or distribution problems." The agency's Regulatory Procedures Manual⁹ explains the logic. Staff are told to recommend a market withdrawal designation for tampering cases with no evidence of manufacturer or distributor responsibility "since, although the situation may present a health hazard, there is no one identified as responsible for the violation." That reasoning traces back to the tampering cases described in our history of the 1982 poisonings.

Who decides which label applies

Companies act first, and FDA sorts the action afterward. Under 21 CFR 7.46(a)², a firm may remove or correct a product "of its own volition and under any circumstances," and that removal "will be considered a recall only if" FDA regards the product as involving a violation subject to legal action. A firm that believes it is running a market withdrawal is asked under section 7.46(d) to consult its FDA district office when complaints or adverse reactions suggest the product is deficient but the cause is unclear.

Inside the agency, center recall units make the call. The procedures manual says market withdrawals and stock recoveries "are not normally entered" into the Recall Enterprise System, FDA's internal recall database, and that a center unit can re-designate an action entered as a recall if it does not meet the definition. FDA's 2022 guidance on initiating voluntary recalls¹⁰ adds in a footnote that its recommendations "could also inform" removals that fall short of a recall, such as a market withdrawal.

One practical result follows. Because withdrawals and stock recoveries stay out of the recall system and out of the public report, FDA publishes no running count of them that compares with its recall totals.

How the Enforcement Report records a recall

Section 7.50 of the recall regulations³ directs FDA to list each new recall weekly by class, whether it was FDA-requested or firm-initiated, and what the firm is doing. The same section says the report "will not include" market withdrawals or stock recoveries, and it lets FDA delay listing certain drug and device recalls when public notice could cause "unnecessary and harmful anxiety" before patients talk to their physicians.

FDA's definitions page⁵ notes that classification usually comes after the firm supplies the information FDA needs, so a recall can appear first as "Not Yet Classified." Each record carries a status (ongoing, completed or terminated), a voluntary or mandated flag, and the method the firm first used to notify customers.

Those flags show how rarely FDA compels anything. Of 18,076 drug recall product records published from June 2012 through Oct. 28, 2026, 18,012 are marked "Voluntary: Firm initiated" and 29 "FDA Mandated," according to openFDA. The first notice went out by letter in 9,267 records, by telephone in 2,710 and by press release in 2,595. Our explainer on voluntary and mandatory recalls covers the legal background, and the GxRadar recall tracker charts the records by year, class and reason.

Sources: GxRadar analysis of openFDA enforcement data by report date, through Oct. 28, 2026, and of the drug recalls page export⁸ through Oct. 21, 2026. Events can contain many product records.

The announcements page runs on a separate track. The agency says on its recall information page⁷ that posting company notices there "is separate from FDA's recall classification process," and that not every recall gets a press release. The 2019 public warning guidance¹¹ goes further, stating that when FDA reposts a firm's announcement it does so as a public service and it "does not necessarily mean that the situation is urgent." Notices on the combined Recalls, Market Withdrawals, & Safety Alerts page⁶ stay up for three years before moving to an archive.

Where safety alerts fit

In FDA's recall vocabulary, "safety alert" is a device term. The background page defines a medical device safety alert as a notice issued when a device "may present an unreasonable risk of substantial harm," adding that some of these situations are also recalls. The procedures manual limits that designation to devices that are not violative and says it "does not pertain to safety alerts designated by other Centers."

For medicines, the alerts most readers see come from two other programs. MedWatch¹², FDA's reporting program, publishes safety alerts for prescription and over-the-counter drugs among other products. Drug Safety Communications¹³ describe newly identified risks of a medicine used as labeled, and FDA says the findings may lead it to require changes to the prescribing information or Medication Guide. FDA's list shows six such communications dated in 2026 through Sept. 15 and seven in 2025.

For reading the news, the distinction matters. A recall concerns specific lots that FDA considers violative. A Drug Safety Communication usually concerns every lot of a drug, because the issue is the drug's effects, and it typically ends in a label change. Our pieces on how MedWatch reports work and on the FAERS database trace how those signals are collected.

A public warning is a third thing again. Under the recall rules it is part of a recall strategy, reserved for urgent situations, and the 2019 guidance says FDA has generally issued or sought one for Class I recalls. Our companion piece on recall depth and effectiveness checks explains how that decision is made.

Reading a notice with the labels in mind

FDA's consumer page on drug recalls¹⁴ says plainly that "not all recalls are announced on FDA.gov or in the news media" and that public notice generally comes when a product was widely distributed or poses a serious hazard. It says the recalling company's instructions govern what consumers should do and directs questions to a doctor or pharmacist. A pharmacy letter about a market withdrawal, a press release about a recall that FDA has not yet classified, and a weekly Enforcement Report line can all describe related events at different stages.

Lot numbers settle most questions about whether a package at home is affected, and our lookup guide shows where to find them. In the 90 days through Oct. 28, 2026, the Enforcement Report added 206 drug recall records, 19 of them Class I, and new records post to the GxRadar feed each week as FDA classifies them.